GlobeNewswire Inc.··Silexion Therapeutics CorpSilexion Advances SIL204 Pancreatic Cancer Program With Manufacturing Deal, Ethics Approval
Silexion initiates GMP manufacturing of SIL204 siRNA therapy with Catalent and secures ethics approval for Phase 2/3 pancreatic cancer trial in Israel.
SLXNSLXNWregulatory approvalpancreatic cancer